Business Description
OKYO Pharma Limited is a UK-based medical company focused on creating new treatments for eye inflammation and eye pain. Their main drug, urcosimod, is currently being tested in multiple clinical trials targeting conditions such as dry eye disease, nerve-related eye pain, and allergic eye conditions. The company is also working on a separate treatment called OK-201, aimed at both short-term and long-term eye pain relief. Founded in 2007 and based in London, OKYO Pharma continues to advance its pipeline toward addressing unmet needs in eye care.
